NCT02563418

Brief Summary

The purpose of this study is to know the limits of feasibility of a reliable oculomotor record for patient with Huntington's disease.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

September 8, 2015

Completed
22 days until next milestone

First Posted

Study publicly available on registry

September 30, 2015

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
Last Updated

September 30, 2015

Status Verified

September 1, 2015

Enrollment Period

3 years

First QC Date

September 8, 2015

Last Update Submit

September 29, 2015

Conditions

Huntington Disease

Keywords

video oculography

Outcome Measures

Primary Outcomes (1)

  • saccadic measures with the eye tracker

    one measure in the evening and one in the afternoon

    1 day

Study Arms (1)

Patient with Huntington's disease

EXPERIMENTAL
Device: Eye-tracking

Interventions

Eye-trackingDEVICE
Patient with Huntington's disease

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Corrected visual acuity \>1/10
  • Aged over 18 years
  • Patient with the mutation that is to say the presence of an abnormal number of trinuclide: CAG\> 38 in the first exon of the huntingtin gene.
  • Total Functional Capacity Scale (CFT) ≥ 3

You may not qualify if:

  • Patients or trustworthy person who have not given their written consent, informed and signed.
  • Patients are not affiliated or who are not entitled to Social Security
  • Private patients of liberty by administrative or judicial decision, or patients supervision
  • Associated disease with neurological repercussions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Universitaire

Angers, 49000, France

RECRUITING

MeSH Terms

Conditions

Huntington Disease

Interventions

Eye-Tracking Technology

Condition Hierarchy (Ancestors)

Basal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDementiaChoreaDyskinesiasMovement DisordersHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCognition DisordersNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Eye Movement MeasurementsDiagnostic Techniques, OphthalmologicalDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosis

Central Study Contacts

Sophie Hue

CONTACT

33 (0)241353800sophie.hue@chu-angers.fr

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 8, 2015

First Posted

September 30, 2015

Study Start

May 1, 2014

Primary Completion

May 1, 2017

Last Updated

September 30, 2015

Record last verified: 2015-09

Locations

FR(1)